BRASILIA (Reuters) – Brazilian health regulator Anvisa is planning to loosen certain requirements for the emergency use authorization of COVID-19 vaccines, according to a source with knowledge of the matter.
Among the measures Anvisa is considering scrapping is a requirement that Phase III tests be performed locally in order for a vaccine to be eligible for emergency use approval in Brazil, said the source, who requested anonymity to discuss private matters.
(Reporting by Ricardo Brito; Writing by Gram Slattery; Editing by Stephen Eisenhammer)
